Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a manufacturing agreement with Hong Kong based Modern Dental Group. Modern Dental have extensive expertise in the manufacture of dental appliances and hold the required quality management certifications for medical device manufacture.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
A clinical study completed earlier this year showed the company's first generation product the O2Vent Mono(TM) is successful in treating OSA and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.
According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.
Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.
The daily commute from Geelong to Melbourne just got a little more perilous with a new study warning one fifth of Australian adults have fallen asleep while driving. Research from the Sleep Health Foundation also shows nearly a third of Australians drive while drowsy at least once a month. They're figures Geelong dentist Dr Joseph Juric said are only scratching the surface.
Treatment for sleep apnoea usually involves either a mask or a mouthguard. A new Australian invention combines the best elements of both. Brisbane dentist Chris Hart spent years struggling to sleep. He snored constantly. He often woke up during the night because he had stopped breathing because of a n obstruction in his nose and throat.
Oventus Medical Ltd (ASX:OVN) is pleased to provide the Company's latest Investor Presentation.
Australian medical device company Oventus Medical Ltd. (ASX:OVN), has lodged an FDA 510k submission for its O2Vent W device - an oral appliance intended to reduce or alleviate snoring, mild to moderate obstructive sleep apnoea and severe sleep apnoea when the patient is intolerant to Continuous Positive Airway Pressure Devices.
Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX:OVN) is pleased to announce significant progress has been made regarding the clinical validation of the Oventus O2Vent oral appliances and, in particular, validation of the benefit of the Oventus proprietary airway.
Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX:OVN) is pleased to announce significant clinical progress made with the Oventus O2Vent oral appliance with a Positive Airway connection.
Oventus Medical Ltd (ASX:OVN) will unveil latest advancements in the field, which are changing the way the disease is treated, in San Francisco next week (April 20th). Dr Chris Hart will join more than 30 international speakers at 3DHEALS2017 - the first collaborative conference in the U.S. aiming to create a global healthcare community focusing on 3D printing and related technologies.
Oventus Medical Ltd (ASX:OVN) Investor Update: Achieves Significant Milestones in Last Quarter and Expands Commercialisation of O2Vent T
Oventus Medical Ltd (ASX:OVN) are pleased to provide the Company's latest Investor Update. Oventus have achieved a number of significant milestones in the last quarter, expanding the commercialisation efforts of our O2Vent(TM) T device in numerous geographical regions and strengthening our sales and operational systems.
During the half-year the principal activities of Oventus Medical Ltd (ASX:OVN) (the Company) consisted of the commercialisation and distribution of the O2Vent(TM) T, in Australia, as well as development of a pipeline or products to treat segments of the snoring and sleep and apnoea market.